iSpheric gains US approval

Article

The iSpheric Model YA-60BB intraocular lens (IOL) (Hoya) has received FDA approval.

The iSpheric Model YA-60BB intraocular lens (IOL) (Hoya) has received FDA approval.

The foldable hydrophobic IOL, which is already available in Europe and Asia, features a blue-light blocker and can be implanted through an un-enlarged incision. In a clinical trial, 98% of the 600 enrolled subjects reported best corrected visual acuity (BCVA) of ≥20/40 from one-month postoperatively until the final 12-month follow-up visit. No significant adverse events were reported.

The iSpheric will have its official launch at this year's American Academy of Ophthalmology (AAO) meeting, which will be held November 8–11 in Atlanta, GA, US. The lens will be shipped to facilities in the US by the end of the year, and a new version, available in the iSert pre-loaded injector system, will be available in early 2009.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.